Abbott Laboratories logged a 2.8% change during today's afternoon session, and is now trading at a price of $98.17 per share. On average, analysts give it a target price of $124.94.
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. The large-cap company is based in the United States. Abbott Laboratories currently returns an annual dividend yield of 2.1%.
What to Consider if You Are Thinking of Buying Abbott Laboratories:
-
Abbott Laboratories has moved 1.0% over the last year.
-
ABT has a forward P/E ratio of 21.2 based on its EPS guidance of 4.62.
-
Over the last 6 years, earnings per share (EPS) have been growing at a compounded average rate of 48.8%.
-
The company has a price to earnings growth (PEG) ratio of -10.36.
-
Its Price to Book (P/B) ratio is 4.58
Abbott Laboratories Has Irregular Cash Flows
| Date Reported | Cash Flow from Operations ($ k) | Capital expenditures ($ k) | Free Cash Flow ($ k) | YoY Growth (%) |
|---|---|---|---|---|
| 2023-02-17 | 9,581,000 | -1,777,000 | 11,358,000 | -8.54 |
| 2022-02-18 | 10,533,000 | -1,885,000 | 12,418,000 | 23.22 |
| 2021-02-19 | 7,901,000 | -2,177,000 | 10,078,000 | 29.64 |
| 2020-02-21 | 6,136,000 | -1,638,000 | 7,774,000 | 1.04 |
| 2019-02-22 | 6,300,000 | -1,394,000 | 7,694,000 | 14.75 |
| 2018-02-16 | 5,570,000 | -1,135,000 | 6,705,000 |
Abbott Laboratories's free cash flows have a decent average of $9.34 Billion over the last 6 years, but they are highly variable since their coefficient of variability is 22847377364.4%. The compounded average growth rate over this period is 0.0%.
